Announcements Trials
Browse Landscape

Phase

Phase 1 37Phase 2 22Phase 3 8Phase 1/2 8Phase 4 2Phase NA 1Phase 2/3 1

Status

Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 16Breast 6Gynecologic 3Tumor-Agnostic 2NET 2Head & Neck 2Endocrine 2Other solid neoplasm 1CNS 1

Conditions

Neoplasms, Second Primary 1Neoplasms 1

Interventions

Drug Therapy 5Docetaxel 3Bevacizumab 3icotinib 2Vincristine 2Pemetrexed 2Misoprostol 2Genes, p53 2Gemcitabine 2Dexamethasone 2Carboplatin 2Aspirin 2pinaverium 1pentetreotide 1pembrolizumab 1pazopanib 1olaparib 1netupitant, palosentron drug combination 1nedaplatin 1lorlatinib 1durvalumab 1ceritinib 1atezolizumab 1Zoledronic Acid 1Water 1Vitamin E 1Vemurafenib 1Ultracet 1Triamcinolone 1Trastuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Carboplatin × Tumor-Agnostic × Clear all
NCT02283424 2014-11-05

Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With EGFR Gene Mutation

Chinese PLA General Hospital

Phase 4 Unknown
10 enrolled
Tumor-Agnostic

Neoplasms, Second Primary

NCT02103244 2014-04-03

Validation of an Adjusted Dosing Algorithm of Carboplatin

Rijnstate Hospital

Phase 4 Unknown
24 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡